SCHEMBL3247348

SCHEMBL3247348

FC(F)(F)c1cccc(Nc2nccc(-c3ccnc4[nH]ccc34)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.58
CLK1 P49759 1/20 0.56
CLK2 P49760 1/20 0.56
DYRK1A Q13627 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
DYRK1B Q9Y463 1/20 0.56
CDK2 P24941 6/20 0.56
GSK3B P49841 6/20 0.56
CDK4 P11802 1/20 0.54
MTOR P42345 1/20 0.52
SMG1 Q96Q15 1/20 0.52
CCNB2 O95067 3/20 0.52
CDK1 P06493 3/20 0.52
CCNB1 P14635 3/20 0.52
CCNB3 Q8WWL7 3/20 0.52
RET P07949 2/20 0.52
KDM4E B2RXH2 1/20 0.48
IDH2 P48735 1/20 0.48
BRAF P15056 1/20 0.48
KDR P35968 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3244117 0.86 SYK (0.55) CDK2GSK3BCCNB2CDK1CCNB1
SCHEMBL3246773 0.84 NUDT1 (0.61) CDK2CDK4SMG1CCNB2CDK1
SCHEMBL3252559 0.83 CDK2 (0.57) AURKACLK1CLK2DYRK1ACLK4
SCHEMBL13357453 0.83 CDK1 (0.55) AURKACLK2DYRK1ACLK4DYRK1B
SCHEMBL3250914 0.83 CDK2 (0.57) AURKACLK1CLK2DYRK1ACLK4
SCHEMBL3247346 0.81 CLK1 (0.59) AURKACLK1CLK2DYRK1ACLK4
SCHEMBL3247308 0.80 PIK3CG (0.65) AURKACLK2DYRK1ACDK2GSK3B
SCHEMBL857777 0.80 PTK6 (0.61) AURKARETKDM4EIDH2BRAF
SCHEMBL3244107 0.80 CDK2 (0.56) AURKACLK1CLK2DYRK1ACLK4
SCHEMBL3244322 0.79 GSK3B (0.54) CDK2GSK3BCCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 EP claimed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 US claimed
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 EP disclosed
EP-1896470-B1 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-05-26 EP disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 US disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 US disclosed
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors TOYO BOSEKI KABUSHIKI KAISHA (JP) 2008-12-04 US disclosed
EP-1896470-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-03-12 EP disclosed
WO-2006124863-A2 PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300267-A1 Compounds and Compositions as Protein Kinase Inhibitors ERBB2, JAK2, AURKC AURKA 54/4885CLK1 1000/4885CLK2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.